CJC-1295 + Ipamorelin 2mg — Vial Spec, Reconstitution Math & COA

Overview of the CJC-1295 + Ipamorelin 2mg Vial Format

In laboratory research environments, the cjc-1295 + ipamorelin 2mg vial format serves as a specialized, low-volume reference standard designed for preliminary screening, receptor binding kinetics, and acute dose-response trials in rodent models. A 2mg total peptide fill typically consists of a 1:1 mass ratio (1mg of CJC-1295 Without DAC and 1mg of Ipamorelin), yielding a defined dual-action peptide matrix. Researchers selecting this specific mass unit are often conducting short-term in vitro cellular assays or small-cohort animal studies where long-term storage of reconstituted liquid stock presents unnecessary degradation risks.

While standard inventory offerings may fluctuate based on production schedules and laboratory demand, PX1 Research provides comprehensive analytical coverage across all blend configurations. If the 2mg presentation is temporarily restricted or out of stock, investigators can reference our primary multi-dose format, such as the CJC-1295 No DAC / Ipamorelin 10mg Blend, or explore alternative quantities across our full research peptide catalog. Both 2mg and higher-yield preparations utilize identical solid-phase peptide synthesis (SPPS) protocols, ensuring complete analytical parity regardless of total lyophilized vial mass.

Dual-Mechanistic Synergy: GHRH Activation and GHSR Agonism

The co-formulation of CJC-1295 (a synthetically modified growth hormone-releasing hormone analog) and Ipamorelin (a selective ghrelin/growth hormone secretagogue receptor agonist) represents one of the most thoroughly evaluated dual-pathway systems in preclinical neuroendocrinology. CJC-1295 acts directly upon the GHRH receptor on anterior pituitary somatotrophs, activating the adenylate cyclase/cAMP signal transduction cascade. This mechanism promotes the transcription and release of endogenous growth hormone (GH) stores.

Concurrently, Ipamorelin selectively targets the Growth Hormone Secretagogue Receptor (GHSR-1a). Preclinical studies suggest that activating GHSR-1a triggers intracellular calcium mobilization via the phospholipase C (PLC) pathway. When applied simultaneously in animal models, these two distinct pathways act synergistically: CJC-1295 amplifies the baseline amplitude of GH release, while Ipamorelin synchronizes the pulsatile frequency. In vitro data indicate that this dual activation stimulates sustained GH secretion and downstream insulin-like growth factor 1 (IGF-1) expression far more effectively than either compound isolated at an equivalent mass.

Reconstitution Chemistry & Volumetric Math for 2mg Vials

Accurate reconstitution of a cjc-1295 + ipamorelin 2mg vial requires precise volumetric calculation based on the total lyophilized mass of both active pharmaceutical ingredients (APIs). Because the vial contains 2.0 mg (2000 mcg) of total active peptide mass, the resulting concentration is directly dictated by the volume of laboratory-grade diluent added. Bacteriostatic Water (0.9% benzyl alcohol preserved sterile water) or Sterile 0.9% Sodium Chloride for Injection are standard laboratory diluents.

To achieve target working concentrations for volumetric micro-pipetting, researchers should apply the following diluent ratios:

• Reconstitution with 1.0 mL Diluent: Yields a final concentration of 2.0 mg/mL (2000 mcg/mL). Each 0.01 mL (10 µL or 1 unit on a standard U-100 syringe) delivers 20 mcg of total peptide matrix (10 mcg CJC-1295 / 10 mcg Ipamorelin).

• Reconstitution with 2.0 mL Diluent: Yields a final concentration of 1.0 mg/mL (1000 mcg/mL). Each 0.01 mL (10 µL or 1 unit) delivers 10 mcg of total peptide matrix (5 mcg CJC-1295 / 5 mcg Ipamorelin).

• Reconstitution with 3.0 mL Diluent: Yields a final concentration of 0.667 mg/mL (666.7 mcg/mL). Each 0.01 mL (10 µL or 1 unit) delivers approximately 6.67 mcg of total peptide matrix.

To eliminate calculation errors during bench preparation, laboratory personnel are encouraged to utilize our interactive peptide reconstitution calculator, which accounts for variable vial masses, diluent types, and target aliquot volumes.

Aliquot Planning, Handling, and In Vitro Stability Protocols

Maintaining chemical integrity across the research cycle requires strict adherence to physical handling protocols. Lyophilized peptide cakes containing CJC-1295 and Ipamorelin exhibit high thermal stability in their dry state when stored at sub-zero temperatures (-20°C to -80°C). However, once reconstituted in aqueous solvent, the peptide bonds become vulnerable to hydrolysis, oxidation, and aggregation.

When managing a 2mg vial format, aliquot planning is critical to prevent repeated freeze-thaw cycles, which induce mechanical shear stress and degrade active sequence purity. Post-reconstitution, liquid solutions should be partitioned into single-use micro-centrifuge tubes using sterile, low-binding polypropylene tips. Aliquots intended for immediate use within a 7- to 14-day evaluation window should be stored at 2°C to 8°C. For extended assay timelines exceeding 14 days, aliquoted samples must be flash-frozen and maintained at -80°C to preserve primary structural conformation and prevent peptide cleavage.

Comparative Analysis: 2mg Vials vs. High-Yield 5mg and 10mg Formulations

Selecting the appropriate vial size depends entirely on the scale, duration, and design of the experimental model. The 2mg vial configuration is optimized for pilot feasibility studies, single-dose receptor binding assays, or short-term micro-dosing protocols involving small rodent cohorts. Because small-volume fills are reconstituted with lower diluent volumes, the entire volume is consumed rapidly, minimizing the duration the peptide spends in liquid solution and virtually eliminating aqueous degradation risks.

Conversely, high-throughput animal studies, longitudinal tissue repair trials, or multi-animal research models generally benefit from larger vial formats. For example, utilizing a CJC-1295 No DAC / Ipamorelin 10mg Blend reduces per-milligram reagent overhead and streamlines bulk assay preparation. However, larger fills necessitate rigorous aliquot management to safeguard the solution against contamination and loss of potency over extended handling periods.

Analytical Verification: HPLC Purity, Mass Spectrometry & Lot-Matched COAs

PX1 Research enforces strict quality control standards for every production batch. Because synthetic peptide blends contain two distinct amino acid sequences within a single matrix, rigorous analytical validation is mandatory to ensure precise stoichiometry and high molecular purity.

Every production lot undergoes independent testing at an ISO 17025-accredited laboratory using High-Performance Liquid Chromatography (HPLC) and Liquid Chromatography-Mass Spectrometry (LC-MS). HPLC verification guarantees an overall chemical purity of ≥98%, while LC-MS confirms the exact molecular weights of both CJC-1295 (MW: ~3367.9 g/mol) and Ipamorelin (MW: ~711.86 g/mol). Furthermore, kinetic chromogenic LAL assays confirm that bacterial endotoxin levels remain strictly below <0.01 EU/mg, preventing baseline cellular toxicity or unintended immune responses in sensitive assays. Researchers can inspect batch-specific certificates of analysis directly via our COA lookup hub.

Comparative Peptide Research: GHRH Analog and Secretagogue Combinations

Understanding how the CJC-1295 + Ipamorelin blend performs relative to single-agent or alternative GHRH/GHRP formulations is essential for optimal experimental design. While CJC-1295 No DAC features a short biological half-life (~30 minutes) ideal for mimicking physiological GH pulses, CJC-1295 DAC includes a Drug Affinity Complex that covalently binds to plasma albumin, extending its clearance half-life to several days and resulting in continuous GH elevation.

When evaluating alternative secretagogues within the same functional class, researchers frequently analyze Sermorelin, a truncated 29-amino-acid GHRH fragment, or potent second-generation GHRP compounds such as GHRP-2. Additionally, high-potency GHRH analogs like Tesamorelin are frequently studied for their specific effects on visceral adipose tissue metabolism and hepatic gene expression. In comparative animal models, the CJC-1295 + Ipamorelin pairing is uniquely favored due to Ipamorelin’s exceptional selectivity, which stimulates GH release without triggering marked elevations in plasma cortisol or prolactin.

Downstream IGF-1 Expression and Tissue Repair Assays

The primary objective of studying GHRH analogs in combination with growth hormone secretagogues centers on their ability to regulate downstream endocrine pathways involved in cellular regeneration. Preclinical models demonstrate that systemic elevation of growth hormone leads to rapid hepatic synthesis and secretion of Insulin-like Growth Factor 1 (IGF-1). IGF-1 binds to receptor tyrosine kinases across various somatic tissues, driving mitotic signaling, cellular proliferation, and extracellular matrix remodeling.

In animal models of musculoskeletal injury, sustained elevation of the GH/IGF-1 axis via CJC-1295 + Ipamorelin administration has been shown to accelerate collagen synthesis, promote satellite cell activation in skeletal muscle, and improve tendon-to-bone healing kinetics. In vitro research utilizing osteoblast and chondrocyte cell lines further reveals enhanced extracellular matrix mineralization and glycosaminoglycan synthesis. These findings highlight the utility of this dual-peptide matrix as a standard reagent for examining tissue repair, wound healing velocity, and nitrogen balance restoration in preclinical research.

Investigators studying these regenerative mechanisms can review comprehensive literature and experimental designs hosted within our public research library.

Storage, Handling, and Contamination Control in Laboratory Environments

To ensure reproducible data across experimental replicates, standard operating procedures (SOPs) for handling lyophilized 2mg vials must be strictly enforced. Upon receipt, un-reconstituted vials should be stored immediately in a temperature-monitored freezer (-20°C or colder) protected from direct light exposure.

During reconstitution, all vial septa must be sanitized using 70% isopropyl alcohol wipes prior to needle insertion. Diluents should be introduced slowly along the glass wall of the vial to minimize turbulence and prevent mechanical foaming, which can induce physical denaturation of the secondary peptide structures. Swirl the vial gently until the cake completely dissolves into a clear, colorless solution; never vortex active peptide mixtures. Laboratory personnel seeking high-volume procurement or institutional account configurations can review options through our wholesale laboratory portal.